Exemestane is a steroidal, irreversible (suicidal) aromatase inhibitor. Unlike anastrozole and letrozole which reversibly bind to aromatase, exemestane permanently destroys the aromatase enzyme molecules it binds to. The body must synthesize new aromatase enzymes to restore estrogen production. This suicidal mechanism eliminates the estrogen rebound effect that occurs when discontinuing reversible AIs. For AAS users, exemestane is often preferred over anastrozole because of its milder lipid impact, slight androgenic properties, and lack of rebound. It is the only AI that some experienced coaches consider acceptable in limited use during PCT.
Notes
Exemestane was FDA-approved in 1999 for advanced breast cancer treatment. Its suicidal mechanism and milder lipid impact make it the preferred AI for many experienced AAS users. The steroidal structure provides mild androgenic effects that differentiate it from non-steroidal AIs. The key clinical advantage in the bodybuilding context is the lack of estrogen rebound — when stopping exemestane before PCT, estrogen rises gradually as new aromatase is synthesized rather than rebounding sharply.
Exemestane is an androgen analogue that irreversibly binds to the substrate-binding site of the aromatase enzyme (CYP19A1). Upon binding, it is processed by aromatase into a reactive intermediate that forms a covalent bond with the enzyme, permanently inactivating it — hence the term "suicide inhibitor." The enzyme molecule is permanently destroyed and cannot convert any further androgens to estrogens. The body must produce new aromatase enzyme molecules to restore estrogen production, which takes approximately 2-3 days. At 25mg/day, exemestane suppresses plasma estradiol by approximately 85%. Notably, exemestane has mild intrinsic androgenic activity — its steroidal structure allows it to interact weakly with the androgen receptor.
Oral bioavailability is approximately 5% fasting, but INCREASES BY 40% when taken with a fatty meal — always take with food. Peak plasma concentration in 1-2 hours. Moderately protein-bound (90%). Extensively metabolized hepatically via CYP3A4 and aldoketoreductases. Despite the 24-27 hour half-life of the parent compound, the pharmacological effect persists because the enzyme destruction is permanent. New aromatase enzyme synthesis takes approximately 2-3 days. Metabolites are excreted in urine and feces.
Typical Dose
On-cycle estrogen control: 12.5mg every other day (most common). High-dose aromatizing cycles: 25mg every other day. Sensitive individuals: 12.5mg twice weekly. Light estrogen management: 12.5mg twice weekly or as needed.
Frequency
Every other day (EOD) is standard. Some users dose twice weekly (E3.5D). Daily 25mg dosing is aggressive and rarely needed.
Administration
Oral tablet, taken WITH food (a fatty meal increases bioavailability by 40%). Available in 25mg tablets.
Half-Life
24-27 hours (but effect is permanent on bound enzymes — new aromatase takes 2-3 days to regenerate)
Contraindications
Exemestane is NOT a standard PCT compound. However, among the three common AIs, it is the most compatible with PCT if estrogen management is needed during the transition. Some protocols use 12.5mg EOD during the first 1-2 weeks of PCT when transitioning from a high-aromatizing cycle, then discontinue to allow estrogen to support HPTA recovery. This is controversial and should only be done under guidance with frequent bloodwork.